Wir sind mit live! Mehr erfahren

Transcat

TRNS

Börsenwert 752 Mio. $

80,35 USD

-2,26

2,74 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

80,35

0,00

0 %

1 Tag

-2,74 %

5 Tage

-6,95 %

1 Monat

-3,93 %

3 Monate

-10,5 %

6 Monate

5,07 %

Seit Jahresbeginn

40,57 %

1 Jahr

14,95 %

5 Jahre

13,91 %

10 Jahre

695,54 %

Profil: Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.

Mitarbeiter: 1.413

Industrie Spezialisierte Unternehmensdienstleistungen

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 42,9 %

Neutral 57,1 %

Negativ 0 %

Transcat Holdings: Recent Share Price Weakness Provides A Solid Entry Point

Transcat is rated BUY, leveraging a mission-critical, high-retention calibration services business with strong operating leverage and recurring revenue. TRNS delivered robust Q1 FY27 results: revenue rose 22% YoY, service segment operating income surged 35% YoY, and organic service growth was 13% YoY. The stock trades at a 50% discount to its recent EV/EBITDA peak, despite forward EBITDA growth 70% above the industrial sector median.

Transcat Holdings: Recent Share Price Weakness Provides A Solid Entry Point

Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical.

Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical

Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September.

Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September

Transcat, Inc. (TRNS) Q1 2027 Earnings Call Transcript

Transcat, Inc. (TRNS) Q1 2027 Earnings Call Transcript

Transcat, Inc. (TRNS) Q1 2027 Earnings Call Transcript

Transcat Q1 Earnings Call Highlights

Transcat NASDAQ: TRNS reported first-quarter fiscal 2027 revenue of $92.9 million, up 22% from a year earlier, as both its calibration services and distribution segments posted double-digit growth. The company said demand remained strong across its regulated end markets, including life sciences, aerospace and defense, and energy.

Transcat Q1 Earnings Call Highlights

Zacks Investment Research

Transcat, Inc. (TRNS) Q1 Earnings and Revenues Top Estimates

Transcat, Inc. (TRNS) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.59 per share a year ago.

Transcat, Inc. (TRNS) Q1 Earnings and Revenues Top Estimates

Transcat Reports Strong Fiscal First Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Service Gross Margin Expansion

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Reports Strong Fiscal First Quarter 2027 Results with Double-Digit Service Organic Revenue Growth and Service Gross Margin Expansion.

Transcat Reports Strong Fiscal First Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Service Gross Margin Expansion

Transcat to Host First Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, August 4, 2026 at 4:30 p.m. Eastern Time

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat to Host First Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, August 4, 2026 at 4:30 p.m. Eastern Time.

Transcat to Host First Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, August 4, 2026 at 4:30 p.m. Eastern Time

Transcat: Mission Critical Company With A Strong Moat

Transcat, Inc. is rated BUY, leveraging recurring revenue from government-mandated calibration services and a strong competitive moat. TRNS's growth is driven by high-margin services, strategic M&A, and recent expansion into Latin America, targeting life sciences and regulated industries. Despite a 58% YTD share price gain, TRNS trades at 18x forward EV/EBITDA, well below its historical peak valuation multiples.

Transcat: Mission Critical Company With A Strong Moat

Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer.

Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt